New Delhi, Jul 24 (PTI) Sun Pharmaceutical Industries on Thursday said it has settled an antitrust litigation in the US entailing a payment of USD 200 million.

The subsidiaries of the company, Sun Pharmaceutical Industries, Inc. (SPII) and Taro Pharmaceuticals USA, Inc. have signed a settlement agreement with the End Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania, US, the Mumbai-based drugmaker said in a regulatory filing.

Also Read | Is NOIDA Tax-Free? Will Residents of Noida Not Have To Pay Tax From FY 2024-25? Check Who Gets Tax Exemptions and How.

"Under the terms of the settlement agreement, the subsidiaries will make an aggregate payment of USD 200 million in exchange for a full release of all claims asserted against them in the End Purchaser Action by the settlement class members," it added.

The settlement amounts may be reduced if more than a certain percentage of the total insured class members opt out of the putative class, the company stated.

Also Read | Bodoland Lottery Result Today, July 24, 2025: Assam State Lottery Sambad Thursday Lucky Draw Results Declared, Check Winners List With Ticket Numbers.

The settlement agreement is subject to court approval, it added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)